Page 1

Vitrolife Not for release , publication or distribution , in whole or in part , directly or indirectly , in or into Australia , Canada , Japan , the United States or any other country where such publication , distribution or release would be unlawful or require additional documents to be prepared or registered or require any other actions to be taken , in addition to the requirements under Swedish law . This press release is not a prospectus or an offer for sale of securities . Securities may not be sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933 , as amended . Vitrolife does not intend to register any part of the offering in the United States or to conduct a public offering of the shares in the United States . Other restrictions are applicable . Please see " Important information " and " Information to distributors " at the end of the press release . Press Release July 8 , 2021 Gothenburg , Sweden Vitrolife acquires Igenomix and creates a global leader in reproductive health Vitrolife AB ( publ ) ( “ Vitrolife ” ) has entered into a definitive agreement to acquire 100 % of the shares in Igenomix S.L.1 ( " Igenomix " ) from EQT and other shareholders ( together the " Sellers " ) . The combination will create a global leader in reproductive health by combining the knowledge , product portfolios and market presence of two leading companies within IVF medical devices and reproductive genetic testing services . Igenomix - a global leader in reproductive genetic testing services Igenomix is a global leader in women's health and reproductive genetic testing services for IVF clinics founded in 2011. Igenomix today operates 26² labs globally and offers a wide portfolio of clinically validated genetic tests and services covering a wide range of genetic diagnostics in reproductive and personalized medicine , where the pre - implantation tests constitute the major revenue driver . Igenomix has demonstrated a proven track record of driving profitable growth through innovation and international expansion . The head office is in Valencia , Spain and the company has approximately 560 employees as of December 2020. Igenomix is expected to achieve estimated revenue for the last twelve months as of June 2021 of EUR 122 million ( EUR 98 million excluding Covid - 19 testing ) which would imply a compound annual growth rate ( CAGR ) from 2017 to 2021 of approximately 37 % ( 29 % excluding Covid - 19 testing revenue ) ³ . The company expects to achieve adjusted earnings before interest , taxes , depreciation , and amortization ( EBITDA ) for the last twelve months as of June 2021 of EUR 36 million ( EUR 26 million excluding Covid - 19 testing EBITDA ) . The Igenomix net sales for the last twelve months as of June 2020 amounted to EUR 79 million ( EUR 76 million excluding Covid - 19 testing revenue ) and adjusted EBITDA of EUR 17 million ( EUR 16 million excluding Covid - 19 testing EBITDA ) . The combination of Igenomix and Vitrolife creates a global leader in reproductive health Through this transaction , the combined company will be able to better serve its customers across the entire IVF journey . Combining Igenomix's portfolio of reproductive genetic testing services with Vitrolife's best - in - class IVF device portfolio creates a leading IVF platform with the ambition to deliver long - term profitable growth . Through the enhanced scale and synergistic product offering , Vitrolife can better serve clinics , professional staff , and patients around the world . Specifically , the combination enables the two companies to leverage each other's respective commercial networks which will allow the combined group to cross - sell products and offer enhanced solutions to its customers as well as sharing knowledge in driving innovation . " The combination of Igenomix and Vitrolife brings together two